Indaptus Therapeutics Inc's stock surged by 23.92% in pre-market trading, reaching a 20-day high. This movement follows a significant after-hours increase of 64.65% after the company completed a $6 million financing agreement with investor David E. Lazar, who purchased preferred shares, indicating strong investor confidence in the company's future potential.
The surge is attributed to the completion of a securities purchase agreement with David E. Lazar, who invested $6 million in preferred stock, enhancing the company's financial stability and leadership structure. This financing is expected to support future initiatives, and the appointment of Lazar as Co-CEO is seen as a positive step towards improving governance and shareholder engagement. Despite the broader market's decline, this positive development has led to a notable increase in stock price, suggesting sector rotation as investors react favorably to the company's restructuring efforts.
The implications of this financing and leadership change could be significant for Indaptus Therapeutics, as it positions the company for potential growth and recovery in the coming months. Investors are likely to keep a close eye on the upcoming shareholder meeting scheduled for March 31, 2026, which will address the preferred stock conversion and board elections.
Wall Street analysts forecast INDP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast INDP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INDP is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.190
Low
10.00
Averages
10.00
High
10.00
Current: 2.190
Low
10.00
Averages
10.00
High
10.00
No data
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
